BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, November 22, 2024
See today's BioWorld
Home
» Amphista raises $53M to expand its protein degradation portfolio
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Amphista raises $53M to expand its protein degradation portfolio
March 17, 2021
By
Nuala Moran
No Comments
LONDON – Targeted protein degradation (TPD) specialist Amphista Therapeutics Ltd. has delivered yet another demonstration of investor interest in the field, closing a $53 million series B.
BioWorld
Financings
Cancer
Series B
